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Dr David M. Jablons (San Francisco, Calif). I have 3 ques-
tions. When you did RT-PCR, what statistical method did you
use to validate the cutoff, and how did you choose a cutoff for an
arbitrary positive or negative value of 2.7?
Dr Yamashita. I used the cutoff point by using the estimation of
normal samples, because I alwaysmeasured the expression ofDYRK21308 The Journal of Thoracic and Cardiovascular Surby using normal expression samples, messenger expression. The cut-
off point is 2.7, and more than 2.7 of DYRK2 expression is positive.
Dr Jablons. Did you do that by a training set and a validation?
Dr Yamashita. No. We have to do that.
Dr Jablons. Second, have you looked at patients with more ad-
vanced stage non–small cell lung cancer to see whether this gene
actually has any prognostic and/or even predictive value, especially
in relationship to alleged sensitivity to a platinum-based doublet
chemotherapy?
Dr Yamashita. These samples were obtained from stage I to
stage IIIA. I haven’t checked stage IV or more aggressive tumors.
Dr Jablons.Was this gene predictive in patients with stage IIIA
disease?
Dr Yamashita. Unfortunately, I estimated the expression of
IIIA in the small samples. However, in our analysis, tumor size
and the DYRK2 expression are prognostic factors. I think that
IIIA is more—no, I or II has a depressed expression of DYRK2.
Maybe IIIA or IV should be downregulated of DYRK2. I’m not
sure, so I have to check by staging.
Dr Jablons. One last question: You mentioned in the manu-
script that BAC tumors had a higher expression. Do you think
that your prognostic value is represented by the fact that you are
picking up more BAC tumors in the stage I patient population?
Dr Yamashita. Not yet. That is an important question. I will
check the DYRK2 expression in BAC. So I have to check the prog-
nosis according to the DYRK2 expression in BAC.gery c December 2009
